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ABSTRACT
Thetriazinederivative12459isapotentG-quadruplex
interacting agent that inhibits telomerase activity.
This agent induces time- and dose-dependent telo-
mere shortening, senescence-like growth arrest and
apoptosis in the human A549 tumour cell line. We
show here that 12459 induces a delayed apoptosis
that activates the mitochondrial pathway. A549 cell
lines selected for resistance to 12459 and previously
characterized for an altered hTERT expression also
showed Bcl-2 overexpression. Transfection of Bcl-2
into A549 cells induced a resistance to the short-
term apoptotic effect triggered by 12459, suggest-
ing that Bcl-2 is an important determinant for the
activity of 12459. In sharp contrast, the Bcl-2 over-
expression was not sufficient to confer resistance
to the senescence-like growth arrest induced by
prolonged treatment with 12459. We also show that
12459 provokes a rapid degradation of the telomeric
G-overhang in conditions that paralleled the apop-
tosis induction. In contrast, the G-overhang degrada-
tion was not observed when apoptosis was induced
by camptothecin. Bcl-2 overexpression did not mod-
ify the G-overhang degradation, suggesting that this
event is an early process uncoupled from the final
apoptotic pathway.
INTRODUCTION
Telomeres play an important role in chromosome structural
integrity to cap and protect their extremities from illegitimate
recombination, degradation and end-to-end fusion (1).
Telomere replication is sustained in proliferative somatic
cells and in most cancer cells by telomerase, a ribonucleo-
protein complex that elongates the chromosome ends to com-
pensate losses occurring at each cell division, due to the
inability of polymerase to fully replicate telomeric extremities
(2). In somatic cells, the absence of telomerase provokes a
progressive shortening of the telomeric DNA at each round
of division that ultimately leads to replicative senescence,
onceacriticaltelomerelengthhasbeen reached (3). Numerous
observations, notably that inhibition of telomerase activity
limits tumour cell growth (4), have led to the proposition
that telomere and telomerase are potential targets for cancer
chemotherapy (3,5,6).
In humans, the telomere is composed of tandem repeats of
the G-rich duplex sequence 50-TTAGGG-30, with a G-rich 30
strand extending beyond the duplex to form a 130–210 base
overhang (G-overhang) (7,8). Telomeres are believed to exist
in different conformations together with several telomere-
associated proteins, such as TRF1, TRF2 and Pot1 (9). The
G-overhang is either accessible for telomerase extension in
an open state, or inaccessible in a capped (or closed) con-
formation that involves the formation of a T-loop motif (9).
Although the T-loop structure has not been deﬁned in detail,
it may be created by the invasion of the G-overhang into the
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doi:10.1093/nar/gki514duplex part of the telomere (10). Uncapping of the telomere
ends by different means leads to telomeric dysfunction char-
acterized by end-to-end fusion, inappropriate recombination,
anaphase bridges and G-overhang degradation that either lead
to apoptosis or senescence (11–14).
Because of the repetition of guanines, the G-overhang is
prone to form a four-stranded G-quadruplex structure that has
been shown to inhibit telomerase activity in vitro (15,16).
Small molecules that stabilize G-quadruplex are effective
as telomerase inhibitors and several series of compounds
have been reported to date to induce replicative senescence
after long-term exposure of tumor cell cultures (17–24).
Among them, the 2,4,6-triamino-1,3,5-triazine derivative
12459 (Figure 1a) is one of the most active and selective
ligands that bind to the telomeric G-quadruplex. The triazine
derivative 12459 was shown to induce both telomere shorten-
ing and apoptosis in the human lung adenocarcinoma A549
cell line (17). Recent results have indicated that 12459 induces
short-term apoptotic effects independent of the presence of
telomerase activity and that resistance to 12459 is associated
with telomere capping alterations in which hTERT over-
expression is essential (25). Clones selected for resistance
to 12459-induced apoptosis also presented hTERT splicing
alterations and/or hTERT overexpression suggesting that cel-
lular events associated with 12459 resistance are complex
(26). These resistant clones were able to maintain a high
level of hTERT transcript and telomerase activity under
12459 treatment (26).
Our studies have demonstrated that another G-quadruplex
ligand, telomestatin, interfered with the conformation and the
length of the telomeric G-overhang, an effect that is thought
to be more relevant than the double-stranded telomere erosion
as a marker for telomestatin cellular activity (27). G-overhang
degradation was found to be associated with the onset of
senescence. Interestingly, telomestatin presented the remark-
able property to remain bound to the telomere ends (27).
In an effort to better understand the mechanism(s) associ-
ated with the cellular activity of 12459, we have analyzed in
thisstudythe characteristicsoftheapoptosisinducedby12459
in A549 cells and the effect of this ligand on the conformation
and the length of the telomeric G-overhang. Our results indic-
ate that the apoptotic protein Bcl-2 also plays a role in the
resistance to the short-term treatment of 12459. In contrast,
Bcl-2 was not found to be a critical determinant of the
long-term senescence induced by 12459. We also observed
a rapid degradation of the telomeric G-overhang induced by
short-term treatment with 12459 that paralleled the apoptotic
induction, which was not observed in A549 cells undergoing
apoptosis by camptothecin.
MATERIALS AND METHODS
Cell culture and drug treatments
Human A549 lung carcinoma cell line was obtained from
the American Type Culture Collection (Rockville, MD) and
12459 resistant A549 clones, JFD18 and JFD9 were obtained
as described previously (25). Cells were cultured in DMEM
with Glutamax (Invitrogen) and supplemented with 10% fetal
calf serum and antibiotics. A549::Bcl-2 cell line was obtained
by transfection of parental A549 cells by pcDNA3Bcl-2 vector
(a gift from L. Debussche, Sanoﬁ-Aventis, Vitry sur Seine,
France) with Lipofectamine
TM 2000 kit and further selection
with geneticin was done for 3 weeks.
For drug treatment, the triazine derivative 12459 (synthes-
ized according to patent WO-0140218) was prepared in
dimethyl sulfoxide (DMSO) at 10 mM. This stock solution
was kept at  20 C in aliquots. Further dilutions were per-
formed in water to be added at the appropriate concentration
to cell cultures in the exponential phase of growth.
Figure 1. (a) Chemical formula of 12459. (b) Effect of 12459 (10 mM) on the
growth of human A549 lung carcinoma parental cells, and resistant A549 cells
JFD18 and JFD9 for the indicated times. Mean – SD of triplicate independent
experiments. (c) Apoptosis induction by 12459 (10 mM) in A549, JFD18 and
JFD9 cells after 96 h of treatment. Cells were fixed and stained with Hoechst
33342, and the percentage of cells exhibiting apoptotic nuclei was calculated
relative to untreated cells.
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by MTT, the survival assay for this compound was performed
in 12-wellplates,each point intriplicate. The number ofviable
cells was counted for trypan blue dye exclusion in a hemato-
cytometer.
Camptothecin was commercially available (Sigma) and was
dissolved in DMSO at 1 mM. Further dilutions were made in
water.
Detection of apoptotic cells
Cells were grown in 12-well plates and were treated with
appropriate concentrations for 1–4 days. During apoptosis,
some adherent A549 cells rounded and detached themselves
from the layer. Thus apoptosis was monitored on both attached
and ﬂoating cells. Cells were washed with phosphate-buffered
saline (PBS) and stained with Hoechst 33342 at 1 mg/ml. Cells
with apoptotic morphology (cell shrinkage, nuclear chromatin
condensation or apoptotic bodies) were counted in different
parts of the slide by ﬂuorescence microscopy. For camp-
tothecin, in parallel to single-strand overhang experiments,
A549 cells were grown for apoptotic evaluation. After 48 h,
control cells or cells treated with 5 mM camptothecin were
ﬁxed with 5% paraformaldehyde in PBS, and then dyed
with DAPI. After mounting in Citiﬂuor (Sigma), cells were
observed with an Axiovert 200M inverted microscope (Zeiss)
equipped with an LD achroplan 40· objective. Images were
collected with a CCD cooled camera (Coolsnap HQ, Ropper
Scientiﬁc).
Long-term culture
For long-term cell growth studies, cells were seeded at 15 ·
10
3 cells/ml into a 25 cm
2 tissue culture ﬂask, in the presence
or the absence of 12459 (0.5 mM), cultured for 4 days, then
trypsinized and counted. At each passage, 15 · 10
3 cells/ml
were replated onto a new culture ﬂask with fresh medium
containing drug solution. Results were expressed as the cumu-
lated population doubling (PD) as a function of the time of
culture as previously described (17).
Detection of SA b-galalactosidase activity
At 4 and 7 days after plating on 24-well microplate in the
presence of 0.1 to 10 mM 12459, the endogenous senescence-
associated b-galactosidase activity was assessed by a staining
using X-Gal (5-bromo-4-chloro-3-indolyl-ß-D-galactopyrano-
side) as described previously (28).
b-galactosidase activity was also evaluated at day 20 for
long-term culture with 0.5 mM 12459. The culture plates were
placed on the stage of an inverted microscope (Nikon TE300)
and observed at 20· magniﬁcation. Images were recorded as a
650· 515 array with a CCD cooled camera (Coolsnap, Ropper
Scientiﬁc).
Western blot analysis
All experiments were performed with cells in a logarithmic
phase by controlling the plating density. Cells were washed
with ice-cold PBS and lysed in RIPA buffer (50 mM Tris–HCl
(pH 7.4), 0.25% sodium desoxycholate, 150 mM NaCl, 1 mM
EDTA, and 1 mM PMSF), including a protease inhibitor cock-
tail at 1 mg/ml (Mini complete protease, Roche Diagnostics).
After 30 min on ice, lysates were cleared by centrifugation.
Protein concentration was routinely measured with the
Bio-Rad protein assay. Cell lysates containing equal amounts
of total protein (25–40 mg) were resolved on a 12% or 10%
SDS–PAGE, transferred to a PVDF membrane (Macherey-
Nalgel) by electroblotting in 25 mM Tris (pH 8.3), and
192 mM glycine. Membranes were blocked for 3 h at room
temperature in 10 mM Tris (pH 7.5) containing 0.15 M NaCl,
0.1% Tween-20 and 5% non-fat dry milk. Primary and sec-
ondary immunodetection, as well as washes, were performed
in the same buffer using 5% dry milk. Western blot analysis
was accomplished according to standard procedure using
SuperSignal West Pico chemiluminescent substrate (Pierce).
The following primary antibodies were used (1:1000 unless
otherwiseindicated):Monoclonalantibody toactiveCaspase3
(Imgenex), Monoclonal anti-b-actin clone AC-15 (1:10000)
and anti-Bcl-2 clone 100 (Sigma), monoclonal anti-cleaved
PARP asp 214 (Cell signalling) and anti-Bax (Santa Cruz).
Mitochondrial membrane potential (Dcm) and Reactive
Oxygen Species (ROS) production
Fluorescence from JC1 monomers (green) and J-aggregates
(red) was speciﬁc to the mitochondrial membrane potential
(Dym) state (low and high, respectively). Therefore, the red/
green ﬂuorescence intensity ratio allowed the characterization
of mitochondrial function. After washing twice, JC-1 emission
was recorded by spectroﬂuorimetry to follow the quantitative
evolutionof(Dym)intreatedcellscomparedwithcontrolcells.
Cells were seeded into 25 cm
2 tissue culture ﬂasks. After 24 h,
cells were treated with appropriate concentrations of 12459 for
different incubation times. The cells were washed and labeled
with3mMJC1in5mlﬁnal volume for45min.Cellswere then
trypsinized and resuspended in 2 ml RPMI without phenol red
for spectroﬂuorimetric analysis using 488 nm as excitation
wavelength. Relative membrane potential was expressed as:
(I590 nm/I530 nm + I590 nm) · 100. The protonophore carbonyl
cyanide m-chlorophenylhydrazone (CCCP, Sigma) was used
as positive control for potential disruption.
ROS production was determined using carboxy ﬂuorescein-
AM (CF). After cell treatment, 5 mM CF was added to 5 ml
ﬁnal volume for 30 min. Trypsinized cells were then analyzed
by spectroﬂuorimetry using 488 nm for excitation and 515 nm
for ﬂuorescence emission measurement.
Solution hybridization experiments
The non-denaturing hybridization assay to detect the 30 telo-
mere G-overhang was performed as described previously (27).
A total of 2.5 mg aliquots of undigested genomic DNA was
hybridized at overnight 50 C with 0.5 pmol of [g 
32P]ATP-
labeled (50-CCCTAA-30)4 oligonucleotide (21C) in sodium
hybridization buffer (10 mM Tris–HCl (pH 7.9), 50 mM
NaCl, and 1 mM EDTA) in a volume of 20 ml. For competition
with Pu22myc (50-GAGGGTGGGGAGGGTGGGGAAG-30)
the reactions were performed in the presence of 10 mM
Pu22myc. Reactions were stopped by the addition of 6 ml
of loading buffer (20% glycerol, 1 mM EDTA, and 0.2% bro-
mophenol blue). Hybridized samples were size-fractionated
on 0.8% agarose gels in 1· TBE buffer containing ethidium
bromide (EtBr). Gels were dried on Whatman ﬁlter paper.
Ethidium ﬂuorescence and radioactivity were scanned in a
phosphorimager (Typhoon 9210, Amersham). The procedure
2194 Nucleic Acids Research, 2005, Vol. 33, No. 7allows detection of the amount of single-strand overhang
available for hybridization. Results were expressed as the
relative hybridization signal normalized to the ﬂuorescent
signal of EtBr.
Real-time PCR analysis
Total RNA was isolated from 1 · 10
6 cells using RNeasy Mini
Kit (Quiagen).An aliquot of 1 mg RNA was reverse transcribed
using a reverse transcription kit (Promega). Real-time PCR
was performed with QuantiTect
TM SYBR-Green PCR Kit
(Quiagen) on the Lightcycler
TM system (Roche diagnostics).
Theexpression levelofBaxandBcl-2werenormalizedby18S
ribosomal RNA level of the same sample. Reaction mixtures
contained 10 mlo f2 · Quantitect SYBR-Green PCR Master
Mix, 2 ml of reverse-transcriptase-generated cDNA in a ﬁnal
volume of 20 ml containing primers (Proligo, Paris, France)
at 125 nM. The primer sequences for 18S ribosomal RNA gene
were: 50-CCCTCCAATGGATCCTCGTT-30 for the forward
primer, and 50-AGTGACGAAAAATAACAATACAGGAC-
TCT-30 for the reverse primer. The primer sequences for
Bax were: 50-TTCCGAGTGGCAGCTGACAT-30 for the for-
ward primer, and 50-TTCCAGATGGTGAGTGAGGC-30 for
the reverse primer. The primer sequences for Bcl-2 were:
50-GGTGAACTGGGGGAGGATTGT-30 for the forward
primer, and 50-CTTCAGAGACAGCCAGGAGAA-30 for the
reverse primer. After an initial incubation step at 95 C for
8 min, 25–30 PCR cycles were performed. The cycling con-
ditions consisted of a denaturation at 95 C for 10 s, annealing
either at 60 C for 5 s for 18S and Bax, or at 58 C for Bcl-2 and
extended at 72 C for 7 s. To conﬁrm ampliﬁcation speciﬁcity,
the PCR products were subjected to a melting curve analysis.
Relative gene expression was expressed as a ratio of the
expression level ofthe gene ofinterestto that of18S ribosomal
RNA, with values in untreated A549 cells deﬁned as 100%.
RESULTS
12459 induces delayed apoptosis mediated by
the mitochondrial pathway
We have previously shown that the triazine derivative 12459
(Figure 1a) has a dose-dependent dual antiproliferative effect
on the A549 human tumor cell line (17). Apoptosis occurred
after short-term treatments with concentrations >4 mM and a
senescence-likedelayedgrowtharrestwasobservedafterlong-
term treatments with concentrations <1 mM (17,18). A char-
acteristic feature of the short-term effect of 12459 on A549
cells is a delayed action, since both antiproliferative effects
and ﬁnal morphological changes associated with apoptosis
were observed at 48 h. As shown in Figure 1b, a signiﬁcant
decrease in A549 cell proliferation was observed at 48 h but
not at 24 h in the presence of 10 mM 12459. In agreement,
nuclear morphological changes characterizing apoptosis were
detected after 48 h and reached 20% of the total cells at day 4
(Figure 1c). Therefore, 12459-induced apoptosis presents a
signiﬁcant and characteristic delay, as compared with other
well known antitumor agents, such as camptothecin.
In order to further characterize the apoptotic response trig-
geredby12459,wehavealsousedA549cellswithanacquired
resistance to 12459. The resistant clones JFD18 and JFD9
were obtained after an EMS mutagenesis and a soft agar
cloning in the presence of 10 mM 12459 (25). In agreement
with the delayed apoptotic response induced by 12459, dif-
ferences in the cell viability characterizing the resistance of
these clones were observed after a 48 h delay (Figure 1b).
JFD clones were also found to be resistant to 12459-induced
apoptosis, as evaluated by Hoechst staining. Apoptotic nuclear
bodies were observed in 5–8% of resistant JFD18 and JFD9
cells, as compared to 20% of sensitive A549 cells after 96 h of
drug treatment with 10 mM 12459 (Figure 1c), thus indicating
a steep decrease in the ﬁnal steps of the apoptotic pathway.
The resistance to 12459 might represent upstream processes
such as accessibility to the ligand, modiﬁcations of the intra-
cellular targets, or direct relationship to the ﬁnal apoptotic
pathway itself. We have previously shown that the expression
of the multidrug resistant factors (MDR1, MRP1, MRP2,
MRP3 and BCRP) was not modiﬁed in these resistant clones
[(25) and data not shown]. Telomerase, which is thought to be
one of the intracellular targets of this G-quadruplex ligand,
was found to be overexpressed in JFD18 cells but remained at
a normal level in JFD9 cells (25,26), suggesting that additional
mechanisms might be involved in 12459 resistance.
We have examined here some of the characteristics of
the apoptotic pathway induced by 12459. The expression of
anti- or pro-apoptotic proteins belonging to the Bcl-2 family is
known to determine events associated with the mitochondrial
onset of apoptosis. Western blot analysis indicated a signiﬁc-
ant increase of Bax after 24 h of 12459 treatment (Figure 2b);
and under the same conditions, a decrease of Bcl-2 was
observed after 48 h of drug treatment (Figure 2a and b). Sim-
ilar results were found at the transcriptional level by using
quantitative RT–PCR analysis (Figure 2c and d). An alteration
in the Bcl-2/Bax balance at both protein and mRNA levels was
provoked by 12459, as previously reported for DNA damaging
agents (29).
Western blot analysis indicated that Bax protein levels were
unchanged in untreated JFD18 and JFD9 clones, as compared
with A549 cells (Figure 2b). In addition, 12459-induced
overexpression of Bax was not modiﬁed in these clones
after 24 and 48 h of drug treatment. In contrast, the Bcl-2
protein level was increased in untreated JFD9 and JFD18
clones (Figure 2b). Furthermore, JFD18 and JFD9 cells main-
tained a high level of Bcl-2 under 12459 treatment. Quantit-
ative RT–PCR analysis of the transcripts of these genes
conﬁrmed these ﬁndings at the transcriptional level (result
not shown) and suggested that activation of Bcl-2 activation,
and not of Bax, is associated with the resistance phenotype.
We also studied the time course of caspase-3 activation.
Western blot analysis revealed a delayed and time-dependent
appearance of the active proteolytic fragment of caspase-3,
which was detected after 36 h of treatment with 12459
(Figure3b,see alsoFigure4c). Inagreement, caspase degrada-
tion of the native 116 kDa PARP yielding a 89 kDa proteolytic
fragment was evident after 36 h of treatment with 12459
(Figure 3a, see also Figure 4b). In contrast, the activation
of caspase-8, which is involved in the death receptor path-
way of apoptosis, was very low and remained at background
levels under 12459 treatment (result not shown). In addition,
12459-induced apoptosis was inhibited in the presence of the
DEVD-FMK caspase-3 inhibitor but not with the IETD-FMK
caspase-8 inhibitor (Figure 3c), suggests that 12459 triggers
Nucleic Acids Research, 2005, Vol. 33, No. 7 2195the apoptotic cascade essentially through the mitochondrial
pathway.
PARP cleavage was also found to be signiﬁcantly reduced
in JFD resistant clones, as compared to sensitive A549 cells
(Figure 3a). Taken together, these results indicate that the
resistant phenotype of these clones is associated with a reduc-
tion of apoptosis.
We also observed a time-dependent decrease of the mito-
chondrial membrane potential to 75% of control after 12 h
of treatment and to 28% of control after 6 h of treatment with
1 and10mM 12459,respectively(Figure3d). Interestingly and
despite the delay of the ﬁnal onset of the apoptotic cascade
(>36 h), such an effect upon mitochondria reﬂects a rapid
action of the compound that might be related to consequences
of its action on cellular DNA. An increase in ROS was also
induced by 12459 that was detectable after 4 h of treatment in
A549 cells (Figure 3e). The maximal increase in ROS (100%)
was observed after 8 h of treatment (Figure 3e).
Together, our results indicate that 12459 induces a delayed
apoptosis (>36 h) mediated by caspase effectors after an early
mitochondrial response and that the resistant phenotype of the
JFD clones is associated with a reduction of apoptosis which
involves an activation of Bcl-2.
Bcl-2 overexpression induces apoptotic
resistance to 12459
To determine whether the Bcl-2 overexpression is directly
related to the resistance phenotype, we transfected A549 cells
with an expression vector containing Bcl-2 cDNA under the
cytomegalovirus (CMV) promoter (pCDNA3Bcl-2). After
3 weeks of selection, a stable A549::Bcl-2 transfected cell
line was established that presented a 10-fold overexpression
of the Bcl-2 protein, as determined by western blot analysis
(Figure 4a).
Cell viability experiments indicated a marked and delayed
resistance of the transfected cell line to the effect of 12459.
A resistance was observed after a 48-h drug treatment for 10
and 20 mM 12459, and after 72 h for 5 mM (Figure 4d). In
addition,PARP cleavage wasfoundtobesigniﬁcantlyreduced
in A549::Bcl-2 cells treated with 10 mM 12459 since only a
faint cleavage was detected after a 48-h treatment, as com-
pared to A549 parental cells (Figure 4b). Similar results were
found for caspase 3 cleavage (Figure 4c). These data indicate
that the overexpression of Bcl-2 in A549 cells is sufﬁcient to
confer a resistance to the apoptotic effect of 12459. Therefore,
overexpression of Bcl-2 in JFD clones is likely to represents
a modiﬁcation of the apoptotic pathway involved in the
resistance to this ligand.
Bcl-2 overexpression is not sufficient to confer
resistance to senescence induced by long-term
treatment with 12459
Previous studies have indicated that G-quadruplex ligands can
induce a senescence-like phenotype, in which cells arrest their
growth and display important morphological modiﬁcations,
associated with the expression of SA b-galactosidase activity
(17,22,30). Such phenotype has been previously characterized
during long-term treatment with low concentrations of 12459
and was associated with telomere shortening (17). Whether
higher concentrations of 12459 and shorter exposures could
induce senescence, also representing an alternative to the
apoptotic death of the cells, has not been evaluated. We have
therefore studied the appearance of these senescent cells in
bothA549andA549::Bcl-2celllinesfor12459concentrations
ranging from 0.1 to 10 mM and up to 7 days of drug treatment.
SA b-galactosidase positive cells were observed after a four
day delay, with 12459 concentrations as low as 0.3 mMi n
both A549 and Bcl-2 transfected cells (Figure 5a). However,
the amount of SA b-galactosidase positive cells remained
unchanged for A549 and A549::Bcl-2 cell lines and corres-
ponded to a small percentage of the treated-cell population
(in the range of only 3–5%). After 7 days of treatment up to
10 mM, some SA b-galactosidase positive cells were still
observed but represented a small proportion of the remaining
cells, as compared to those undergoing apoptosis (Figure 5b).
These results suggested that senescence induction is a minor
Figure 2. (a and b) Western blot analysis of Bcl-2 and Bax protein expression
performedinA549,JFD18orJFD9controlcells(0)orcellstreatedwith10mM
12459 for 24 or 48 h, as indicated. b-actin was used as a control for protein
loading.(candd)AnalysisofBcl-2andBaxmRNAexpressionbyquantitative
RT–PCR in untreated A549 cells (0) and in A549 cells treated with 10 mM
12459 for 24 or 48 h. Results (mean – SD of triplicates) were normalized
relative to 18S ribosomal RNA level, and expressed relative to untreated
A549 cells, defined as 100%, as described in Materials and Methods.
2196 Nucleic Acids Research, 2005, Vol. 33, No. 7event, as compared to the apoptosis induced by 12459 treat-
ment at this concentration (10 mM).
Despite the small amount of cells in which senescence
was induced, a long-term administration of 12459 at a
sub-apoptotic concentration is able to induce cumulative
events able to impair cell growth. To determine whether
Bcl-2 overexpression is able to protect from the long-
term effect of 12459, we have used 0.5 mM of the ligand,
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Nucleic Acids Research, 2005, Vol. 33, No. 7 2197a concentration able to induce senescence but unable to trigger
apoptosis during short-term treatment of A549 and Bcl-2
transfected cells. In these conditions, A549 cells reached a
growth plateau after 12 days and a complete growth arrest
was observed after 20 days of treatment (Figure 6a). For
A549::Bcl-2 cells, although a signiﬁcant resistance was
observed after 4days, the completegrowth arrest ofthe culture
was also observed after 20 days of treatment. At this time, the
proportion of SA b-galactosidase cells was also found to be
identical in A549- and A549::Bcl-2-treated cells (Figure 6b).
These experiments indicate that Bcl-2 overexpression is not
sufﬁcient to confer resistance to long-term treatment with
12459.
12459 induces an alteration of the
telomeric G-overhang
Recent studies with telomestatin indicated that the telomeric
G-overhang represents one of the direct targets of this ligand.
We have determined here the effect of 12459 on the telo-
meric G-overhang from A549 and A549::Bcl-2 cell lines.
Hybridization of a telomeric C-rich probe (21C) under non-
denaturing conditions allowed the measurement of the
single-stranded G-overhang signal in undigested genomic
DNA samples (27). A quantiﬁcation relative to the EtBr stain-
ing of total genomic DNA indicated that the G-overhang
hybridization signal was similar in A549 and Bcl-2 transfected
cells (Figure 7a and b). Treatment of A549 cells with 10 mM
12459 induced a decrease of the overhang signal to 50–55% of
the control after 72 h (Figure 7a and b). An identical result
was found in A549::Bcl-2 cells (Figure 7a and b), suggesting
that the Bcl-2 overexpression has no inﬂuence on the action of
12459 at the telomeric ends. Interestingly, we noticed that
12459 had a very rapid effect on the telomeric overhangs
of A549 cells since the decrease was detectable within 24 h
of drug treatment.
Previous studies with telomestatin have shown that such
a rapid decrease was on account of a tight binding of the
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2198 Nucleic Acids Research, 2005, Vol. 33, No. 7ligand to the telomeric overhangs, which is mediated by a
G-quadruplex stabilization that further impairs the hybridiza-
tion reaction (27). In order to distinguish between a degrada-
tion and a binding of 12459 to the telomeric overhangs, we
have examinedtheinvitro effectof12459on thehybridization
of the 21C probe to the telomeric overhangs from puriﬁed
genomic DNA. Adding to the hybridization reaction an over-
night incubation of up to 10 mM 12459 did not signiﬁcantly
inhibit the G-overhang signal (Figure 7d). A further increase
of the 12459 concentration to 100 mM resulted in a complete
inhibition of the probe hybridization to the telomeric over-
hangs (Figure 7d and e). Competition experiments with a
c-myc promoter quadruplex (Pu22myc) that is efﬁciently
stabilized by 12459 were used to investigate the mechanism
ofsuchhybridization inhibition(31).TheadditionofPu22myc
oligonucleotide to the reaction reversed most of the 12459-
induced inhibition (Figure 7d and e). This suggested that
12459 is able to inhibit the hybridization reaction through
the formation of G-quadruplexes at telomeric overhangs—
as previously reported for telomestatin (27)—but at a higher
concentration. Such differences between these two ligands
could be explained, in part, by their potency to stabilize telo-
meric quadruplexes. FRET experiments showed that DTm
is only 8 C for 12459 and >20 C for telomestatin (17,27).
The hybridization reaction of 21C to the telomeric overhang,
in the presence of ligands, corresponded to a competition
between 21C and ligands for the telomeric overhang. The
resultant products of the reaction reﬂected the ability of
21C to destabilize telomeric G-quadruplexes as well as to
form a duplex. In the absence of ligands, such equilibrium
was in favour of the duplex formation as previously reported
for oligonucleotides (32). Our result suggests that 12459
induces much less stable G-quadruplexes than telomestatin
at telomeres.
In the presence of 10 mM Pu22myc competitor, the
hybridization reaction on DNA samples from 12459-treated
A549 cells did not display a reversion of the G-overhang
signal decrease (Figure 7c). Therefore, we conclude that the
G-overhang signal loss in 12459-treated A549 cells corres-
ponds toan effective degradationofthe telomeric G-overhang.
Interestingly, the G-overhang degradation seems to correl-
ate with the appearance of the apoptosis in A549 and is also
observed in Bcl-2 transfected cells. This would suggest that
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Figure 5. SA b-galactosidase activity in untreated A549 or A549::Bcl-2 cells
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(10mM,panelb).Observedbyphasecontrastmicroscopy,thecellswith4days’
treatment show the appearance of senescent b-galactosidase positive cells,
while 7 days’ treatment induces the appearance of round apoptotic cells.
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Nucleic Acids Research, 2005, Vol. 33, No. 7 2199the G-overhang degradation is an early event uncoupled from
the apoptotic processes. However, that apoptosis could trigger
the degradation of the telomeric ends through the liberation of
nucleases during the ﬁnal stages of nuclear fragmentation
cannot be excluded. We, therefore, used camptothecin to
induce apoptosis in A549 cells in order to examine the status
of the telomeric G-overhang. Treatment of A549 cells for 24 h
with up to 5 mM camptothecin induced a signiﬁcant apoptotic
process with caspase activation, chromatin condensation and
formation of nuclear bodies (Figure 8c) but did not generate
any signiﬁcant decrease of the telomeric G-overhang signal
(Figure 8a and b). This result suggests that the G-overhang
degradation is a process selectively induced by 12459 at telo-
meric ends that is not observed during the apoptotic response
to camptothecin.
DISCUSSION
The induction of replicative senescence has been described as
one of the characteristics of G-quadruplex ligands. It is now
well established that different series of G-quadruplex ligands,
including 12459, telomestatin, BRACO-19 and RHSP4 induce
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2200 Nucleic Acids Research, 2005, Vol. 33, No. 7the appearance of positive b-galactosidase cells and telomere
shortening after a long-term treatment of a range of tumor cell
lines (19,21–24,30,33,34). We also show here that 12459
induces the appearance of senescent cells after short-term
treatment, in agreement with previous ﬁndings with RHSP4
and BRACO-19 (22,30). However, these senescent cells
represent only a small percentage of the cell population.
This suggests that senescence induction is not the major
mechanism responsible for the short-term biological effect
of these ligands.
Besides senescence, apoptosis was also observed after
treatment with these G-quadruplex ligands. A characteristic
feature of this apoptosis is its delayed appearance varying as a
function of the ligand and the cell line used. Recent studies
with RHSP4, telomestatin and 307A showed that apoptosis
occurred after a 5–12 day delay (22,33–35). Although not
formally shown, the in vivo antitumor effect of BRACO-19
against UXF1138L xenograft is compatible with a rapid
apoptotic tumor kill response (36). We demonstrate here
that 12459 induces apoptosis after a 48-h delay for high drug
concentrations (>5 mM). The apoptotic pathway generated by
12459 is characterized by a dysfunction of the Bcl-2/Bax
balance, caspase 3 and PARP cleavage, suggesting that this
ligand triggers the mitochondrial apoptotic pathway. We also
show here that for short-term treatment, apoptosis predomin-
ates over the appearance of senescent cells, this result repres-
ents the most striking difference from other G-quadruplex
ligands described, which needed a longer delay to achieve
massive apoptosis(22,33–35).
Previous ﬁndings indicated that JFD clones resistant to
the apoptotic effect of 12459 displayed telomere capping
alterations (25). We show here that these clones present an
overexpression of the anti-apoptotic protein Bcl-2. In addition,
A549 cells transfected with Bcl-2 show a resistance to the
apoptotic action of 12459. This correlates with a delayed
activation of the mitochondrial apoptotic cascade (PARP
and Caspase 3 cleavage), indicating that Bcl-2 is one of the
determinants of the apoptotic resistance to this ligand.
Interestingly, we demonstrate that Bcl-2 overexpression is
not sufﬁcient to confer resistance to the long-term effect of
12459. The Bcl-2-transfected A549 cell line entered into a
senescent growth arrest in a similar manner to parental
A549 cells. These data suggest that senescence, which is
not predominant for 12459 short-term treatment, becomes a
critical determinant for responses to a prolonged treatment
with this ligand, as previously reported, under treatment
with other anticancer therapies (37). Thus, we also conclude
that G-quadruplex ligand-directed senescence is uncoupled
from apoptosis.
However, since Bcl-2 is a downstream mitochondrial
effector, and because of the rapid onset of apoptosis by this
12459, the relationship between the short-term effect of this
ligand and its molecular action against telomeres becomes
questionable.
It has been hypothesized that the induction of a quadruplex
structure at the end of the telomeric G-overhang results in
telomere uncapping (6). End-to-end chromosomal fusions or
anaphases bridges, consistent with this hypothesis, have been
reported for G-quadruplex ligands (22,30,35). A recent report
from our group also indicated that telomestatin directly inter-
acts with the telomeric G-overhang from A549 cells and
induced its degradation concomitantly with the delayed loss
of cell viability (27). We have shown here that 12459 presents
a major difference with telomestatin as it induced a rapid
degradation of the telomeric G-overhang that paralleled the
induction of apoptosis in A549 cells.
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induction by CPT (5 mM) in A549 cells after 48 h of treatment (A459 + CPT
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morphology under fluorescence microscopy using an Axiovert 200M inverted
microscope (Zeiss) equipped with a 40· objective.
Nucleic Acids Research, 2005, Vol. 33, No. 7 2201Since the telomeric G-overhang degradation paralleled the
apoptotic response of A549 cells to 12459, such a degradation
might reﬂect a telomeric damage response to 12459 associated
with the ﬁnal growth arrest of the cells. On the other hand,
the G-overhang degradation could be a consequence of the
nuclease release from apoptotic cells. Our results present two
pieces of evidence that the G-overhang degradation rather
reﬂects a speciﬁc telomeric response to 12459. First, the over-
expression of Bcl-2 that counteracts the apoptosis induced
by 12459 is not able to modify the G-overhang degradation
mediated by 12459. Second, the antitumor agent camptothecin
is not able to trigger the G-overhang degradation in conditions
that induce a massive apoptosis.
Interestingly, the G-overhang degradation was detected
within 24 h of treatment, suggesting that this response to
the ligand precedes the onset of the ﬁnal apoptotic cascade.
However, 12459 is able to trigger other rapid cellular events,
such as a decrease of the mitochondrial membrane potential
and an increase of ROS within few hours. Preliminary studies
also indicate that 12459 treatment triggers a p53 response
detectable in <6 h (C. Douarre, unpublished results). Whether
these events are associated with the loss of the telomeric
overhang remains to be determined. Although the combined
effect of ROS and 12459 involved in the G-overhang loss
could not be excluded, the effects of ROS alone are unlikely
to explain it since campthothecin, a known activator of ROS
(38), does not alter the G-overhang. Future work will aim at
determining the importance of this early cellular response in
triggering events involved in the G-overhang degradation.
Finally, G-overhang degradation under the 12459 treatment
would reﬂect the uncapping of the telomeric ends and repres-
ent the alteration of the binding of speciﬁc telomeric factors
or effectors of the G-overhang during the replication. It is
noteworthy that dominant negative TRF2 mimics the effect
of a G-quadruplex ligand; and since TRF2 is involved in the
formation of the T-loop, it is possible that 12459 alters such a
telomeric structure or impairs the transitions between linear
and T-loop states mediated by telomeric proteins (9).
In conclusion, our results demonstrate that the
G-quadruplex ligand 12459 induces a delayed apoptosis
involving the mitochondrial pathway and that this ligand is
effective in the long-term independent of the Bcl-2 status of
the cells. Its biological effect is associated with a speciﬁc
degradation of the telomeric overhang. This ﬁnding supports
the notion that alteration of telomeric ends is one of the main
consequences of the intracellular action of G-quadruplex
ligands.
ACKNOWLEDGEMENTS
The authors wish to thank J.L. Mergny and E. Segal for helpful
discussion, T. Wenner and C. Morrison for critical reading of
the manuscript. The pcDNA3Bcl-2 vector is a kind gift from
L. Debussche and M.N. Mary (Sanofi-Aventis, Vitry-sur-
Seine, France). This work was supported by the ‘Ligue
Nationale contre le Cancer, Comite ´s de la Marne et de la
HauteMarne’andbythe‘AssociationpourlaRecherchecontre
le Cancer’, grant no. 3644. C.D. is supported by a student fel-
lowship from ‘l’Association Re ´gionale pour l’Enseignement
et la Recherche Scientifique et technologique ARERS and by
the‘LiguecontreleCancer,Comite ´ del’Aisne’.Fundingtopay
the Open Access publication charges for this article was
provided by the University of Reims.
Conflict of interest statement. None declared.
REFERENCES
1. Blackburn,E.H. (2001) Switching and signaling at the telomere.
Cell, 106, 661–673.
2. McEachern,M.J., Krauskopf,A. and Blackburn,E.H. (2000) Telomeres
and their control. Annu. Rev. Genet., 34, 331–358.
3. Shay,J.W. and Wright,W.E. (2002) Telomerase: a target for cancer
therapeutics. Cancer Cell, 2, 257–265.
4. Hahn,W.C., Counter,C.M., Lundberg,A.S., Beijersbergen,R.L.,
Brooks,M.W.andWeinberg,R.A.(1999)Creationofhumantumourcells
with defined genetic elements. Nature, 400, 464–468.
5. Lavelle,F., Riou,J.F., Laoui,A. and Mailliet,P. (2000) Telomerase:
atherapeutictargetforthethirdmillennium?Crit.Rev.Oncol.Hematol.,
34, 111–126.
6. Neidle,S. and Parkinson,G. (2002) Telomere maintenance as a target for
anticancer drug discovery. Nature Rev. Drug Discov., 1, 383–393.
7. Makarov,V.L., Hirose,Y. and Langmore,J.P. (1997) Long G tails at
both ends of human chromosomes suggest a C strand degradation
mechanism for telomere shortening. Cell, 88, 657–666.
8. Wright,W.E., Tesmer,V.M., Huffman,K.E., Levene,S.D. and Shay,J.W.
(1997) Normal human chromosomes have long G-rich telomeric
overhangs at one end. Genes Dev., 11, 2801–2809.
9. Smogorzewska,A. and de Lange,T. (2004) Regulation of telomerase by
telomeric proteins. Annu. Rev. Biochem., 73, 177–208.
10. Griffith,J.D., Comeau,L., Rosenfield,S., Stansel,R.M., Bianchi,A.,
Moss,H. and de Lange,T. (1999) Mammalian telomeres end in a large
duplex loop. Cell, 97, 503–514.
11. Blackburn,E.H., Chan,S., Chang,J., Fulton,T.B., Krauskopf,A.,
McEachern,M., Prescott,J., Roy,J., Smith,C. and Wang,H. (2000)
Molecular manifestations and molecular determinants of telomere
capping. Cold Spring Harb. Symp. Quant Biol., 65, 253–263.
12. Li,G.Z., Eller,M.S., Firoozabadi,R. and Gilchrest,B.A. (2003) Evidence
that exposure of the telomere 30 overhang sequence induces senescence.
Proc. Natl Acad. Sci. USA, 100, 527–531.
13. Duan,W., Rangan,A., Vankayalapati,H., Kim,M.Y., Zeng,Q., Sun,D.,
Han,H., Fedoroff,O.Y., Nishioka,D., Rha,S.Y. et al. (2001) Design and
synthesisoffluoroquinophenoxazinesthatinteractwithhumantelomeric
G-quadruplexes and their biological effects. Mol. Cancer Ther., 1,
103–120.
14. Karlseder,J., Smogorzewska,A. and de Lange,T. (2002) Senescence
induced by altered telomere state, not telomere loss. Science, 295,
2446–2449.
15. Davies,J.T. (2004) G-quartet 40 years later: from 50-GMP to molecular
biology and supramolecular chemistry. Angew. Chem. Int. Edit., 43,
668–698.
16. Mergny,J.L., Riou,J.F., Mailliet,P., Teulade-Fichou,M.P. and Gilson,E.
(2002) Natural and pharmacological regulation of telomerase.
Nucleic Acids Res., 30, 839–865.
17. Riou,J.F., Guittat,L., Mailliet,P., Laoui,A., Renou,E., Petitgenet,O.,
Megnin-Chanet,F., He ´le `ne,C. and Mergny,J.L. (2002) Cell senescence
andtelomereshorteninginducedbyanewseriesofspecificG-quadruplex
DNA ligands. Proc. Natl Acad. Sci. USA, 99, 2672–2677.
18. Gomez,D., Aouali,N., Renaud,A., Douarre,C., Shin-Ya,K., Tazi,J.,
Martinez,S., Trentesaux,C., Morjani,H. and Riou,J.F. (2003) Resistance
to senescence induction and telomere shortening by a G-quadruplex
ligand inhibitor of telomerase. Cancer Res., 63, 6149–6153.
19. Kim,M.Y., Gleason-Guzman,M., Izbicka,E., Nishioka,D. and
Hurley,L.H. (2003) The different biological effects of telomestatin and
TMPyP4 can be attributed to their selectivity for interaction with
intramolecular or intermolecular G-quadruplex structures. Cancer Res.,
63, 3247–3256.
20. Nakajima,A., Tauchi,T., Sashida,G., Sumi,M., Abe,K., Yamamoto,K.,
Ohyashiki,J.H. and Ohyashiki,K. (2003) Telomerase inhibition
enhances apoptosis in human acute leukemia cells: possibility of
antitelomerase therapy. Leukemia, 17, 560–567.
21. Gowan,S.M., Heald,R., Stevens,M.F. and Kelland,L.R. (2001) Potent
inhibitionoftelomerasebysmall-moleculepentacyclicacridinescapable
of interacting with G-quadruplexes. Mol. Pharmacol., 60, 981–988.
2202 Nucleic Acids Research, 2005, Vol. 33, No. 722. Leonetti,C., Amodei,S., D’Angelo,C., Rizzo,A., Benassi,B.,
Antonelli,A., Elli,R., Stevens,M., D’Incalci,M., Zupi,G. et al.
(2004) Biological activity of the G-quadruplex ligand RHPS4
is associated with telomere capping alteration. Mol. Pharmacol. 8,
1063–1074.
23. Incles,C.M., Schultes,C.M., Kelland,L.R. and Neidle,S. (2003)
Acquired cellular resistance to flavopiridol in a human colon carcinoma
cell line involves up-regulation of the telomerase catalytic subunit and
telomere elongation. Sensitivity of resistant cells to combination
treatment with a telomerase inhibitor. Mol. Pharmacol., 64,
1101–1108.
24. Gowan,S.M., Harrison,J.R., Patterson,L., Valenti,M., Read,M.A.,
Neidle,S. and Kelland,L.R. (2002) A G-quadruplex-interactive potent
small-molecule inhibitor of telomerase exhibiting in vitro and in vivo
antitumor activity. Mol. Pharmacol., 61, 1154–1162.
25. Gomez,D., Aouali,N., Londono-Vallejo,A., Lacroix,L.,
Megnin-Chanet,F., Lemarteleur,T., Douarre,C., Shin-ya,K., Mailliet,P.,
Trentesaux,C. et al. (2003) Resistance to the short term antiproliferative
activity of the G-quadruplex ligand 12459 is associated with telomerase
overexpression and telomere capping alteration. J. Biol. Chem., 278,
50554–50562.
26. Gomez,D., Lemarteleur,T., Lacroix,L., Mailliet,P., Mergny,J.L. and
Riou,J.F. (2004) Telomerase downregulation induced by the
G-quadruplex ligand 12459 in A549 cells is mediated by hTERT RNA
alternative splicing. Nucleic Acids Res., 32, 371–379.
27. Gomez,D., Paterski,R., Lemarteleur,T., Shin-Ya,K., Mergny,J.L. and
Riou,J.F. (2004) Interaction of telomestatin with the telomeric
single-strand overhang. J. Biol. Chem., 279, 41487–41494.
28. Dimri,G.P., Lee,X., Basile,G., Acosta,M., Scott,G., Roskelley,C.,
Medrano,E.E., Linskens,M., Rubelj,I., Pereira-Smith,O. et al. (1995)
Abiomarker thatidentifiessenescenthumancellsincultureandinaging
skin in vivo. Proc. Natl Acad. Sci. USA, 92, 9363–9367.
29. Leung,L.K. and Wang,T.T. (1999) Differential effects of
chemotherapeutic agents on the Bcl-2/Bax apoptosis pathway in human
breast cancer cell line MCF-7. Breast Cancer Res. Treat.,
55, 73–83.
30. Incles,C.M., Schultes,C.M., Kempski,H., Koehler,H., Kelland,L.R. and
Neidle,S. (2004) A G-quadruplex telomere targeting agent produces
p16-associated senescence and chromosomal fusions in human prostate
cancer cells. Mol. Cancer Ther., 3, 1201–1206.
31. Lemarteleur,T., Gomez,D., Paterski,R., Mandine,E., Mailliet,P. and
Riou,J.F.(2004)Stabilizationofthec-mycgenepromoterquadruplexby
specific ligands inhibitors of telomerase. Biochem. Biophys. Res.
Commun., 323, 802–808.
32. Phan,A.T. and Mergny,J.L. (2002) Human telomeric DNA:
G-quadruplex, i-motif and Watson–Crick double helix.
Nucleic Acids Res., 30, 4618–4625.
33. Shammas,M.A.,Reis,R.J.,Li,C.,Koley,H.,Hurley,L.H.,Anderson,K.C.
and Munshi,N.C. (2004) Telomerase inhibition and cell growth arrest
after telomestatin treatment in multiple myeloma. Clin. Cancer Res.,
10, 770–776.
34. Tauchi,T., Shin-Ya,K., Sashida,G., Sumi,M., Nakajima,A.,
Shimamoto,T., Ohyashiki,J.H. and Ohyashiki,K. (2003) Activity of
a novel G-quadruplex-interactive telomerase inhibitor, telomestatin
(SOT-095), against human leukemia cells: involvement of
ATM-dependent DNA damage response pathways. Oncogene,
22, 5338–5347.
35. Pennarun,G., Granotier,C., Gauthier,L.R., Gomez,D., Hoffschir,F.,
Mandine,E.,Riou,J.F.,Mergny,J.L.,Mailliet,P.andBoussin,F.D.(2005)
Apoptosis related to telomere instability and cell cycle alterations in
human glioma cells treated by new highly selective G-quadruplex
ligands. Oncogene, doi:10.1038/sj.onc.1208468.
36. Burger,A.M., Dai,F., Schultes,C.M., Reszka,A.P., Moore,M.J.,
Double,J.A. and Neidle,S. (2005) The G-quadruplex-interactive
molecule BRACO-19 inhibits tumor growth, consistent with telomere
targeting and interference with telomerase function. Cancer Res.,
65, 1489–1496.
37. Roninson,I.B. (2003) Tumor cell senescence in cancer treatment.
Cancer Res., 63, 2705–2715.
38. Palissot,V., Morjani,H., Belloc,F., Cotteret,S., Dufer,J. and Berchem,G.
(2005) From molecular characteristics to cellular events in
apoptosis-resistant HL-60 cells. Int. J. Oncol., 26, 825–834.
Nucleic Acids Research, 2005, Vol. 33, No. 7 2203